Emergence of a New Gluco-Regulatory Mechanism for Glycemic Control with Dapagliflozin/Exenatide Therapy in Type 2 Diabetes.
Eugenio CersosimoMariam AlatrachCarolina Solis-HerreraBaskoy GozdeJohn AdamsAndrea Hansis-DiarteAmalia GastaldelliAlberto ChavezCurtis TriplittRalph A DeFronzoPublished in: The Journal of clinical endocrinology and metabolism (2023)
Our findings provide strong evidence for the emergence of a new long-lasting, glucose-, insulin/glucagon-independent, gluco-regulatory mechanism via which SGLT2i-induced glycosuria stimulates EGP in T2D patients. SGLT2i plus GLP-1 RA combination therapy is accompanied by superior glycemic control versus monotherapy.
Keyphrases
- glycemic control
- type diabetes
- combination therapy
- blood glucose
- end stage renal disease
- weight loss
- insulin resistance
- transcription factor
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cardiovascular disease
- peritoneal dialysis
- randomized controlled trial
- oxidative stress
- stem cells
- clinical trial
- systemic sclerosis
- blood pressure
- mesenchymal stem cells
- interstitial lung disease
- high glucose
- drug induced
- bone marrow
- disease activity